Agilent (AG8) Stock Forecast & Price Target

2 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AG8 Analyst Ratings

Strong Buy

12 Buy

3 Hold

0 Sell

Based on 15 analysts giving stock ratings to

Agilent

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AG8 Stock 12 Month Forecast

Average Price Target

€154.90

▲(16.68% Upside)

Based on 15 Wall Street analysts offering 12 month price targets for Agilent in the last 3 months. The average price target is €154.90 with a high forecast of €165.46 and a low forecast of €130.63. The average price target represents a 16.68% change from the last price of €132.75.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"97":"€97","166":"€166","114.25":"€114.3","131.5":"€131.5","148.75":"€148.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":165.4634285,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€165.46</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":154.89699201333332,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€154.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":130.6290225,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€130.63</span>\n  </div></div>","useHTML":true}}],"tickPositions":[97,114.25,131.5,148.75,166],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,130.15,132.86641757692308,135.58283515384616,138.29925273076924,141.01567030769232,143.7320878846154,146.44850546153845,149.16492303846155,151.8813406153846,154.59775819230768,157.31417576923076,160.03059334615384,162.7470109230769,{"y":165.4634285,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,130.15,132.05361477025642,133.95722954051283,135.86084431076924,137.76445908102565,139.66807385128206,141.57168862153844,143.47530339179485,145.37891816205126,147.28253293230767,149.18614770256409,151.0897624728205,152.9933772430769,{"y":154.89699201333332,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,130.15,130.1868478846154,130.22369576923077,130.26054365384616,130.29739153846154,130.33423942307692,130.3710873076923,130.4079351923077,130.44478307692307,130.48163096153846,130.51847884615384,130.55532673076922,130.5921746153846,{"y":130.6290225,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":105.909,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.235,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":126.062,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128.268,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":116.121,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.98,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.437,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.42,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.21,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":116.774,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.1,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.6,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.15,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€165.46

Average Price Target€154.90

Lowest Price Target€130.63

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Evie Koslosky

Goldman Sachs

€152.4→€161.11

Buy

21.36%

Upside

Reiterated

09/20/26

Analysts Are Bullish on Top Healthcare Stocks: Agilent (A), Ascendis Pharma (ASND)

John Dunigan

Jefferies

€157.63

Hold

18.74%

Upside

Reiterated

09/17/26

Analysts Conflicted on These Healthcare Names: Agilent (NYSE: A) and Aquestive Therapeutics (NASDAQ: AQST)

Eve Burstein

Bernstein

€156.75

Buy

18.08%

Upside

Reiterated

09/09/26

Analysts Are Bullish on These Healthcare Stocks: Agilent (A), AbSci (ABSI)

Unknown Analyst

UBS

Not Ranked

UBS

€143.69

Hold

8.24%

Upside

Initiated

09/08/26

Agilent (A) Initiated with a Hold at UBS

Kallum Titchmarsh

Morgan Stanley

€152.4

Buy

14.80%

Upside

Reiterated

09/01/26

Morgan Stanley Sticks to Its Buy Rating for Agilent (A)

Daniel Arias

Stifel Nicolaus

€156.75

Buy

18.08%

Upside

Reiterated

08/30/26

Stifel Nicolaus Reaffirms Their Buy Rating on Agilent (A)

Evan Stampler

Wells Fargo

€139.34→€156.75

Buy

18.08%

Upside

Reiterated

08/28/26

Agilent price target raised to $180 from $160 at Wells FargoAgilent price target raised to $180 from $160 at Wells Fargo

Daniel Brennan

TD Cowen

€134.98→€156.75

Buy

18.08%

Upside

Assigned

08/27/26

Agilent Price Target Raised to $180 as Broad-Based Outperformance Drives Attractive Risk-Reward, Says Brennan

David Westenberg

Piper Sandler

€130.63

Hold

-1.60%

Downside

Reiterated

08/27/26

Piper Sandler Sticks to Its Hold Rating for Agilent (A)

Luke Sergott

Barclays

€130.63→€152.4

Buy

14.80%

Upside

Reiterated

08/27/26

Agilent price target raised to $175 from $150 at BarclaysAgilent price target raised to $175 from $150 at Barclays

Casey Woodring

J.P. Morgan

€156.75→€165.46

Buy

24.64%

Upside

Reiterated

08/27/26

Agilent price target raised to $190 from $180 at JPMorganAgilent price target raised to $190 from $180 at JPMorgan

Michael Ryskin

Bank of America Securities

€134.98→€156.75

Buy

18.08%

Upside

Reiterated

08/27/26

Agilent price target raised to $180 from $155 at BofAAgilent price target raised to $180 from $155 at BofA

Vijay Kumar

Evercore ISI

€128.89→€149.79

Buy

12.83%

Upside

Reiterated

08/27/26

Agilent price target raised to $172 from $148 at Evercore ISIAgilent price target raised to $172 from $148 at Evercore ISI

Patrick B Donnelly

Citi

€161.11→€165.46

Buy

24.64%

Upside

Reiterated

08/27/26

Agilent price target raised to $190 from $185 at CitiAgilent price target raised to $190 from $185 at Citi

Dan Leonard

RBC Capital

€134.98→€161.11

Buy

21.36%

Upside

Reiterated

08/26/26

Analysts Offer Insights on Healthcare Companies: Zymeworks (NASDAQ: ZYME), Revolution Medicines (NASDAQ: RVMD) and Agilent (NYSE: A)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Evie Koslosky

Goldman Sachs

€152.4→€161.11

Buy

21.36%

Upside

Reiterated

09/20/26

Analysts Are Bullish on Top Healthcare Stocks: Agilent (A), Ascendis Pharma (ASND)

John Dunigan

Jefferies

€157.63

Hold

18.74%

Upside

Reiterated

09/17/26

Analysts Conflicted on These Healthcare Names: Agilent (NYSE: A) and Aquestive Therapeutics (NASDAQ: AQST)

Eve Burstein

Bernstein

€156.75

Buy

18.08%

Upside

Reiterated

09/09/26

Analysts Are Bullish on These Healthcare Stocks: Agilent (A), AbSci (ABSI)

Unknown Analyst

UBS

Not Ranked

UBS

€143.69

Hold

8.24%

Upside

Initiated

09/08/26

Agilent (A) Initiated with a Hold at UBS

Kallum Titchmarsh

Morgan Stanley

€152.4

Buy

14.80%

Upside

Reiterated

09/01/26

Morgan Stanley Sticks to Its Buy Rating for Agilent (A)

Daniel Arias

Stifel Nicolaus

€156.75

Buy

18.08%

Upside

Reiterated

08/30/26

Stifel Nicolaus Reaffirms Their Buy Rating on Agilent (A)

Evan Stampler

Wells Fargo

€139.34→€156.75

Buy

18.08%

Upside

Reiterated

08/28/26

Agilent price target raised to $180 from $160 at Wells FargoAgilent price target raised to $180 from $160 at Wells Fargo

Daniel Brennan

TD Cowen

€134.98→€156.75

Buy

18.08%

Upside

Assigned

08/27/26

Agilent Price Target Raised to $180 as Broad-Based Outperformance Drives Attractive Risk-Reward, Says Brennan

David Westenberg

Piper Sandler

€130.63

Hold

-1.60%

Downside

Reiterated

08/27/26

Piper Sandler Sticks to Its Hold Rating for Agilent (A)

Luke Sergott

Barclays

€130.63→€152.4

Buy

14.80%

Upside

Reiterated

08/27/26

Agilent price target raised to $175 from $150 at BarclaysAgilent price target raised to $175 from $150 at Barclays

Casey Woodring

J.P. Morgan

€156.75→€165.46

Buy

24.64%

Upside

Reiterated

08/27/26

Agilent price target raised to $190 from $180 at JPMorganAgilent price target raised to $190 from $180 at JPMorgan

Michael Ryskin

Bank of America Securities

€134.98→€156.75

Buy

18.08%

Upside

Reiterated

08/27/26

Agilent price target raised to $180 from $155 at BofAAgilent price target raised to $180 from $155 at BofA

Vijay Kumar

Evercore ISI

€128.89→€149.79

Buy

12.83%

Upside

Reiterated

08/27/26

Agilent price target raised to $172 from $148 at Evercore ISIAgilent price target raised to $172 from $148 at Evercore ISI

Patrick B Donnelly

Citi

€161.11→€165.46

Buy

24.64%

Upside

Reiterated

08/27/26

Agilent price target raised to $190 from $185 at CitiAgilent price target raised to $190 from $185 at Citi

Dan Leonard

RBC Capital

€134.98→€161.11

Buy

21.36%

Upside

Reiterated

08/26/26

Analysts Offer Insights on Healthcare Companies: Zymeworks (NASDAQ: ZYME), Revolution Medicines (NASDAQ: RVMD) and Agilent (NYSE: A)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

LGNDLigand Pharma

DNLIDenali Therapeutics

ACHVAchieve Life Sciences

PMNProMIS Neurosciences

CELCCelcuity

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Agilent

3 Months

Dan LeonardRBC Capital

Success Rate

19/28 ratings generated profit

Average Return

+5.09%

Copying Dan Leonard's trades and holding each position for 3 Months would result in 67.86% of your transactions generating a profit, with an average return of +5.09% per trade.

1 Year

Dan LeonardRBC Capital

Success Rate

23/28 ratings generated profit

Average Return

+22.95%

Copying Dan Leonard's trades and holding each position for 1 Year would result in 82.14% of your transactions generating a profit, with an average return of +22.95% per trade.

2 Years

Daniel AriasStifel Nicolaus

Success Rate

9/11 ratings generated profit

Average Return

+14.33%

Copying Daniel Arias's trades and holding each position for 2 Years would result in 81.82% of your transactions generating a profit, with an average return of +14.33% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AG8 Analyst Recommendation Trends

Rating

May 26

Jun 26

Jul 26

Aug 26

Sep 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AG8 has received 19 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. AG8 average Analyst price target in the past 3 months is 154.90.

Each month's total comprises the sum of three months' worth of ratings.

AG8 Financial Forecast

AG8 Earnings Forecast

Next quarter’s earnings estimate for AG8 is €1.50 with a range of €1.49 to €1.53. The previous quarter’s EPS was €1.41. AG8 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year AG8 has Performed in-line its overall industry.

AG8 Sales Forecast

Next quarter’s sales forecast for AG8 is €1.73B with a range of €1.72B to €1.74B. The previous quarter’s sales results were €1.64B. AG8 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year AG8 has Performed in-line its overall industry.

AG8 Stock Forecast FAQ

What is DE:AG8’s average 12-month price target, according to analysts?

Based on analyst ratings, Agilent’s 12-month average price target is 154.90.

What is DE:AG8’s upside potential, based on the analysts’ average price target?

Agilent has 16.68% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Agilent a Buy, Sell or Hold?

Agilent has a consensus rating of Strong Buy, which is based on 12 buy ratings, 3 hold ratings and 0 sell ratings.

What is Agilent’s share price target?

The average share price target for Agilent is 154.90. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €165.46 ,and the lowest forecast is €130.63. The average share price target represents 16.68% Increase from the current price of €132.75.

What do analysts say about Agilent?

Agilent’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of Agilent?

To buy shares of DE:AG8, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Agilent (AG8) Stock Forecast & Price Target

AG8 Analyst Ratings

AG8 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Agilent

AG8 Analyst Recommendation Trends

AG8 Financial Forecast

AG8 Earnings Forecast

AG8 Sales Forecast

AG8 Stock Forecast FAQ

Detailed List of Analyst Forecasts